Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Precigen's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I5X vs GLUE, ZBIO, ADMA: Buyback Yield % Comparison
For the Biotechnology subindustry, Precigen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Precigen's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (STU:I5X) has a Buyback Yield % of 0.06 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Precigen and its competitors. According to the industry distribution chart, Precigen ranks #83 out of 735 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Precigen's Buyback Yield % too high?
Precigen's current Buyback Yield % is 0.06. Based on the distribution chart, Precigen ranks #83 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Precigen has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Buyback Yield % compare to GLUE and ZBIO?
According to the Biotechnology industry distribution chart, Precigen ranks #83 out of 735 companies for Buyback Yield %. This places Precigen in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Precigen and its competitors. Precigen's current Buyback Yield % is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Fairly Valued. The stock's GF Value™ is €5.21, compared to a current price of €5.40 — trading 3.6% above its estimated fair value. The current Buyback Yield % is 0.06. Precigen's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Precigen (STU:I5X), the current Buyback Yield % is 0.06 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (STU:I5X) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be overvalued.
The current stock price of €5.40 is trading 3.6% above its estimated GF Value™ of €5.21.
GuruFocus considers Precigen to be Fairly Valued.
Key valuation signals for STU:I5X:
Buyback Yield %: 0.06
GF Value™: €5.21 vs. price of €5.40 (3.6% above fair value)
No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
63GF Score
Get the complete analysis for STU:I5X
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I5X has been successfully added to your 
